Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...294295296297298299300301302303304...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Let's Talk about Dex: When do the Benefits of Dexamethasone for Prevention of Bronchopulmonary Dysplasia Outweigh the Risks? (Pubmed Central) -  Jul 14, 2022   
    More recent studies suggest that the timing, dosing, and duration of therapy may have a significant impact on the safety and efficacy of dexamethasone administration and that side effects and harms may be minimized if its use is appropriately targeted. Focusing on studies published since the 2010s American Academy of Pediatrics (AAP) statement on dexamethasone, this review seeks to examine the evidence from recent clinical trials to present the current state of knowledge regarding the systemic dexamethasone administration to prevent BPD in extremely premature infants and how dose, duration, and timing might impact its safety and efficacy in this vulnerable population.
  • ||||||||||  dexamethasone / Generic mfg., gentamicin sulfate / Generic mfg.
    Journal:  Consensus on intratympanic drug delivery for Menière's disease (Pubmed Central) -  Jul 14, 2022   
    ②Due to the ototoxicity of aminoglycosides, the application of intratympanic gentamicin（ITG） in MD patients with good hearing is conservative...③Currently, generally accepted treatment endpoint of ITG is no vertigo attack in a 12-month period or a vestibular loss in objective tests in the affected ear. More studies with high level of evidence are needed to evaluate the drug type, efficacy, and therapeutic endpoint of IT therapy for MD.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Trial completion date, Trial primary completion date:  A Study to Compare Different Ways of Steroid Administration After Total Knee Implantation (clinicaltrials.gov) -  Jul 14, 2022   
    P4,  N=159, Recruiting, 
    Trial completion date: Aug 2030 --> Aug 2032 | Trial primary completion date: Aug 2022 --> Jul 2023 Trial completion date: Sep 2032 --> Apr 2032 | Trial primary completion date: Aug 2022 --> Apr 2023
  • ||||||||||  Erleada (apalutamide) / J&J, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer (clinicaltrials.gov) -  Jul 14, 2022   
    P2,  N=900, Recruiting, 
    Trial completion date: Sep 2032 --> Apr 2032 | Trial primary completion date: Aug 2022 --> Apr 2023 Not yet recruiting --> Recruiting | Initiation date: Jul 2022 --> Feb 2020 | Trial primary completion date: Dec 2029 --> Dec 2026
  • ||||||||||  paclitaxel / Generic mfg., ranitidine hydrochloride / Generic mfg.
    Retrospective data, Journal:  Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study. (Pubmed Central) -  Jul 13, 2022   
    Sixty-three patients did not receive premedication in the form of ranitidine, of whom 10 (15.8%) had a HSR, p-value of .80. In conclusion, we found no difference in the incidence of HSRs during paclitaxel infusions between patients who received ranitidine as premedication versus those who did not.
  • ||||||||||  Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo
    Journal:  Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. (Pubmed Central) -  Jul 13, 2022   
    Significant cytopenias were more common in non-responders (stable or progressive disease) vs. responders (partial or complete response) (100% vs. 70%; p = .01). In the multivariable model, platelet transfusion within a month before leukapheresis, number of red blood cell and platelet transfusions between leukapheresis to lymphodepletion, pre-lymphodepletion absolute neurophil count, pre-lymphodepletion lactate dehydrogenase, and number of dexamethasone treatments after CAR-T were significantly associated with severe cytopenias after axi-cel.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Effects of Dietary L-Theanine on Growth Performance, Antioxidation, Meat Quality, and Intestinal Microflora in White Feather Broilers With Acute Oxidative Stress. (Pubmed Central) -  Jul 13, 2022   
    The three groups were corn-soybean-based diet (NC group); basal diet plus drinking water with 30 mg hydrocortisone/kg (PC group); and basal diet supplemented with 400 mg L-theanine/kg plus drinking water with 30 mg hydrocortisone/kg (LT group)...The relative abundance of Firmicutes in the LT group was significantly higher than in the NC and PC groups (p < 0.05). These results suggested that the effects of acute oxidative stress on growth performance and meat quality of broilers are continuous, and dietary supplementation of L-theanine could improve the growth performance and meat quality, enhance the intestinal mucosal barrier and antioxidant capacity, and improve the composition of the intestinal flora of broilers caused by acute oxidative stress.
  • ||||||||||  verapamil intralesional / Stada
    Journal:  Assessment of various intralesional injections in keloid: Comparative analysis. (Pubmed Central) -  Jul 13, 2022   
    Statistically, a significant difference was observed between groups. Intralesional verapamil reported to be the most effective therapy and platelet-rich plasma was effective as intralesional triamcinolone acetonide with no serious side effects and 5-fluorouracil was less effective in treating the keloids.
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Peripheral Trigeminal Nerve Blocks for Chronic Orbital Pain: Clinical Features and Outcomes. (Pubmed Central) -  Jul 13, 2022   
    The neurologist should be aware that recurrent encephalopathy from adrenal insufficiency can occur regardless of hemodynamic or electrolyte changes on typical hospital metabolic panels. Modulation of trigeminal afferent nerve activity with peripheral trigeminal nerve blocks containing anesthetic with or without dexamethasone may be a promising treatment strategy for chronic orbital pain of diverse etiologies and phenotypes.
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Microscopic colitis in older adults: impact, diagnosis, and management. (Pubmed Central) -  Jul 13, 2022   
    Although there is a lack of unified recommendation for treatment, most clinicians prefer the use of budesonide, and most published guidelines regard this locally acting glucocorticoid as the therapy of choice. In our article, we aimed for a brief, noncomprehensive overview of the clinical significance, diagnosis, and management of microscopic colitis.
  • ||||||||||  hydrocortisone / Generic mfg.
    Review, Journal:  CIRMI-a new term for a concept worthy of further exploration: a narrative review. (Pubmed Central) -  Jul 13, 2022   
    As there is evidence to suggest that in acute critical illness, hyperreninemic hypoaldosteronism, is associated with poor outcomes, co-administration of hydrocortisone with fludrocortisone in patients with septic shock should be considered. In keeping with the concept of CIRCI, we suggest the term critical illness-related mineralocorticoid insufficiency as a more appropriate description of the impaired aldosterone response to increased levels of renin seen in this group of patients.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  Verification of the Efficacy/Safety of the Intratympanic Drug Delivery for Hearing Loss (clinicaltrials.gov) -  Jul 13, 2022   
    P1/2,  N=26, Recruiting, 
    In keeping with the concept of CIRCI, we suggest the term critical illness-related mineralocorticoid insufficiency as a more appropriate description of the impaired aldosterone response to increased levels of renin seen in this group of patients. Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2023
  • ||||||||||  prednisolone / Generic mfg.
    Trial completion date, Trial primary completion date:  High-TeC: Nasal High-Flow in COPD (clinicaltrials.gov) -  Jul 13, 2022   
    P=N/A,  N=136, Recruiting, 
    Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2023 Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Jan 2023 --> May 2023
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment open:  Dexamethasone and Robotic-assisted Hysterectomy (clinicaltrials.gov) -  Jul 13, 2022   
    P=N/A,  N=100, Recruiting, 
    Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Jan 2023 --> May 2023 Not yet recruiting --> Recruiting